IHL - INCANNEX - HOLDERS RESEARCH, page-927

Totally agree.
We just need to get this Redomicile D&D out of the way and move on. New trading platform with OOS not ADR, zero selling pressure with a much wider/larger investment audience and a huge market IND for mental health, inflammation and OSA. Combine this with a way oversold equity in a health care listing that presents sound 28 pathways, highly recognised team, COH to accomplish short term benchmarks, PSI-GAD clinic cashflow short term with 2 pathways entering phase 2/3 trials and short term commercialisation of our gum asset.

IMO once on the NASDAQ the selling pressure in IHL we are experiencing now will be a distant memory in IXHL where focus will be on near term potential. IHL 42X FDA approval deriskd this pathway in a massive scale that has been overlooked by the ASX's fixation on Redomicile up. Everyone I speak to regarding IHL 42X look forward to the day where they have access to a simple administered tablet that could enhance their deep sleep by 50%. I look at this period before listing as the last buying opportunity. The potential here is in the next 12-18 months is massive and it begins with a yes vote in roughly 6 weeks. My vote is a yes.
GLAH